Edward Flores, MD
Pulmonary Disease · Conroe, TXNPI 1912922386
Payments from drug & device makers
Across 286 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Insmed, Inc.$211
- Philips North America LLC$210
- Regeneron Healthcare Solutions, Inc.$163
- Boehringer Ingelheim$135
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,81895%
- Education$2415%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 112 | $1,507 |
| AstraZeneca | 48 | $1,237 |
| Insmed, Inc. | 10 | $211 |
| Philips North America LLC | 12 | $210 |
| Regeneron Healthcare Solutions, Inc. | 6 | $163 |
| Boehringer Ingelheim | 6 | $135 |
| Mallinckrodt Hospital Products Inc. | 10 | $124 |
| Sanofi | 5 | $114 |
| United Therapeutics Corporation | 6 | $110 |
| Johnson & Johnson | 7 | $110 |
| Jazz Pharmaceuticals Inc. | 4 | $108 |
| Pfizer | 6 | $104 |
| Bayer | 4 | $85 |
| Grifols USA, LLC | 4 | $85 |
| Sunovion Pharmaceuticals Inc. | 9 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| LEO Pharma Inc. | 2 | $57 |
| Baxter Healthcare | 3 | $56 |
| Harmony Biosciences LLC | 2 | $52 |
| Amgen | 3 | $50 |
| Verona Pharma, Inc. | 2 | $44 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Genentech USA, Inc. | 3 | $42 |
| Merck | 3 | $40 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $17 |
| Electromed, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Inogen, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$125
- TRELEGY ELLIPTA$117
- BEVESPI AEROSPHERE$100
- FASENRA$100
- AIRSUPRA$100
- TEZSPIRE$100
How this compares
$5,059 in reported general payments places this provider in the 60th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,093 | $835,959 |
| OfevNintedanib Esylate | 65 | $829,700 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 15 | $208,816 |
| Breo ElliptaFluticasone/Vilanterol | 288 | $137,264 |
| TezspireTezepelumab-Ekko | 22 | $92,643 |
| SymbicortBudesonide/Formoterol Fumarate | 83 | $23,327 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $18,940 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 674 | $17,426 |
| Spiriva RespimatTiotropium Bromide | 12 | $9,317 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $9,112 |
| EliquisApixaban | 13 | $8,992 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 23 | $7,012 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,989 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 45 | $6,220 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 17 | $5,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta | $1,507 | $984,1751,416 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $135 | $846,00591 claims |
| Grifols USA, LLCProlastin C | $85 | $208,81615 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $1,237 | $134,910127 claims |
| PfizerEliquis | $104 | $8,99213 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $16 | $2,78512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Conroe
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.